CA2826262C - Bakuchiol compositions for treatment of post inflammatory hyperpigmentation - Google Patents

Bakuchiol compositions for treatment of post inflammatory hyperpigmentation Download PDF

Info

Publication number
CA2826262C
CA2826262C CA2826262A CA2826262A CA2826262C CA 2826262 C CA2826262 C CA 2826262C CA 2826262 A CA2826262 A CA 2826262A CA 2826262 A CA2826262 A CA 2826262A CA 2826262 C CA2826262 C CA 2826262C
Authority
CA
Canada
Prior art keywords
pih
acne
reducing
treatment
inflammatory hyperpigmentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2826262A
Other languages
French (fr)
Other versions
CA2826262A1 (en
Inventor
Mei Feng Hong
Qi Jia
Lidia Alfaro Brownell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unigen Inc
Original Assignee
Unigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigen Inc filed Critical Unigen Inc
Priority to CA3128718A priority Critical patent/CA3128718A1/en
Priority to CA3128715A priority patent/CA3128715A1/en
Priority to CA3128711A priority patent/CA3128711A1/en
Priority claimed from PCT/US2012/023686 external-priority patent/WO2012106551A1/en
Publication of CA2826262A1 publication Critical patent/CA2826262A1/en
Application granted granted Critical
Publication of CA2826262C publication Critical patent/CA2826262C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Post inflammatory hyperpigmentation (PIH) is a unique skin pigmentation condition that can be derived from endogenous inflammatory skin disorders like acne and that involves increased melanin synthesis (melanogenesis) and deposition. Current therapeutic agents against acne are ineffective against PIH. The present disclosure provides using of bakuchiol compositions for alleviating, reducing or treating PIH derived from acne as well as for reducing melanogenesis, reducing melanocyte proliferation or preventing melanocyte apoptosis in a mammal.
CA2826262A 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation Active CA2826262C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA3128718A CA3128718A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128715A CA3128715A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128711A CA3128711A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161438890P 2011-02-02 2011-02-02
US61/438,890 2011-02-02
PCT/US2011/026594 WO2012105990A1 (en) 2011-02-02 2011-03-01 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
USPCT/US2011/026594 2011-03-01
PCT/US2012/023686 WO2012106551A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CA3128718A Division CA3128718A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128711A Division CA3128711A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128715A Division CA3128715A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Publications (2)

Publication Number Publication Date
CA2826262A1 CA2826262A1 (en) 2012-08-09
CA2826262C true CA2826262C (en) 2021-10-26

Family

ID=46603028

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3128715A Pending CA3128715A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128711A Pending CA3128711A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128718A Pending CA3128718A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA2826262A Active CA2826262C (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA3128715A Pending CA3128715A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128711A Pending CA3128711A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
CA3128718A Pending CA3128718A1 (en) 2011-02-02 2012-02-02 Bakuchiol compositions for treatment of post inflammatory hyperpigmentation

Country Status (8)

Country Link
KR (5) KR102333655B1 (en)
CN (2) CN103458882B (en)
AU (1) AU2012212153B9 (en)
BR (1) BR112013019798A2 (en)
CA (4) CA3128715A1 (en)
HK (1) HK1215792A1 (en)
MX (1) MX350719B (en)
WO (1) WO2012105990A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10471035B2 (en) 2014-10-20 2019-11-12 Sunny BioDiscovery Compositions and methods for using esters of meroterpenes and of other resveratrol analogues
CN105675741A (en) * 2015-12-30 2016-06-15 成都九芝堂金鼎药业有限公司 Method for determining content of effective components in hair growing pill
KR20190116858A (en) 2018-04-05 2019-10-15 주식회사 엑소코바이오 A composition comprising an exosome and/or extracellular vesicle derived from stem cell as an active ingredient and its application for preventing, alleviating, reducing or removing postinflammatory hyperpigmentation
CN111544317B (en) * 2020-04-29 2022-01-14 珀莱雅化妆品股份有限公司 Anti-aging composition cationic nano-liposome and preparation method and application thereof
CN114478196B (en) * 2021-01-27 2023-11-10 江苏巴帝恩生物科技有限公司 Method for extracting and purifying bakuchiol from Ulmus pumila root and application of bakuchiol in cosmetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617473B2 (en) 1987-06-30 1997-06-04 キヤノン株式会社 Information input device
KR20130125411A (en) 2005-05-09 2013-11-18 유니젠, 인크. Compositions of bakuchiol and methods of making the same
WO2008143761A1 (en) * 2007-05-14 2008-11-27 Sytheon Ltd. Sunscreen compositions and methods

Also Published As

Publication number Publication date
KR20230058727A (en) 2023-05-03
HK1215792A1 (en) 2016-09-15
KR20210145864A (en) 2021-12-02
MX350719B (en) 2017-09-14
CN105147533B (en) 2018-07-31
KR102333655B1 (en) 2021-12-01
KR102525516B1 (en) 2023-04-24
KR102156731B1 (en) 2020-09-16
KR101954118B1 (en) 2019-03-05
CN103458882A (en) 2013-12-18
CA2826262A1 (en) 2012-08-09
CA3128715A1 (en) 2012-08-09
BR112013019798A2 (en) 2017-07-04
CN105147533A (en) 2015-12-16
MX2013008890A (en) 2013-10-17
KR102642352B1 (en) 2024-02-28
AU2012212153B2 (en) 2017-04-06
WO2012105990A1 (en) 2012-08-09
KR20140008364A (en) 2014-01-21
CA3128718A1 (en) 2012-08-09
AU2012212153B9 (en) 2017-05-11
AU2012212153A1 (en) 2013-08-29
KR20200108120A (en) 2020-09-16
KR20190025740A (en) 2019-03-11
CN103458882B (en) 2015-08-05
CA3128711A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
CA2826262C (en) Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
PH12014501639A1 (en) Pharmaceutical compositions and methods
MX2015011966A (en) Resorcinol compounds for dermatological use.
MX358857B (en) Skin care compositions containing combinations of natural ingredients.
AU2012204164A8 (en) Melanin modification compositions and methods of use
WO2012075419A3 (en) Non-invasive fat reduction by hyperthermic treatment
MX2012013787A (en) Compositions and methods for stimulating magp-1 to improve the appearance of skin.
MX2012000817A (en) Treatment of liver disorders with pi3k inhibitors.
NZ600874A (en) Fluorinated derivatives of deferiprone
CA3010395A1 (en) Method of treating skin with microrna modulators
MX352165B (en) Compounds with anti-aging activities.
MX367091B (en) TOPICAL COMPOSITIONS and METHODS OF USE.
FI20115135L (en) Microfibrillated cellulose for use especially in treating psoriasis and atopic dermatitis
ZA201104743B (en) Topical herbal formulation for treatment of acne and skin disorders
MX365366B (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
EP2558102A4 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
PL2758383T3 (en) Aromatic amidothiazoles, cosmetic and dermatological preparations containing them, and their use for the treatment and prophylaxis of unwanted pigmentation of the skin
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2011125039A3 (en) Cosmetic use of geranylgeranyl-2-propanol
MX2013001979A (en) Methods of treating cellulite
MX2010006987A (en) Topical compositions containing desthiobiotin and its derivatives and a method of treating skin.
PH12017501200A1 (en) A skin lightening composition comprising niacinamide and ilomastat
MX345695B (en) Heterocyclocarbonylaminothiazoles, cosmetic or dermatological preparations containing said heterocyclocarbonylaminothiazoles, and use thereof to combat or prevent undesired pigmentation of the skin.
MX2015015200A (en) "inhibitors of nicotinamide phosphoribosyltransferase, compositions, products and uses thereof".

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170201